Allurion Technologies (NYSE:ALUR) Receives “Neutral” Rating from Chardan Capital

Allurion Technologies (NYSE:ALUR)‘s stock had its “neutral” rating restated by analysts at Chardan Capital in a report issued on Thursday,Benzinga reports. They presently have a $2.50 target price on the stock. Chardan Capital’s price target would indicate a potential downside of 25.37% from the stock’s current price. Chardan Capital also issued estimates for Allurion Technologies’ FY2025 earnings at ($4.39) EPS.

Separately, Roth Mkm restated a “buy” rating and issued a $16.00 target price on shares of Allurion Technologies in a research note on Friday, March 21st.

Allurion Technologies Trading Up 7.7 %

NYSE ALUR opened at $3.35 on Thursday. The stock has a market cap of $16.06 million, a PE ratio of -0.28 and a beta of -0.59. Allurion Technologies has a 12 month low of $2.15 and a 12 month high of $98.75. The company’s 50-day moving average price is $4.01 and its 200-day moving average price is $9.89.

Hedge Funds Weigh In On Allurion Technologies

An institutional investor recently raised its position in Allurion Technologies stock. Geode Capital Management LLC grew its stake in Allurion Technologies Inc. (NYSE:ALUR) by 40.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 516,330 shares of the company’s stock after acquiring an additional 149,484 shares during the quarter. Geode Capital Management LLC owned about 0.80% of Allurion Technologies worth $317,000 at the end of the most recent quarter. 21.39% of the stock is owned by institutional investors.

Allurion Technologies Company Profile

Allurion Technologies Inc focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.